Lifeblood Medical, Inc. has completed an
important strategic plan towards entering the Tissue Preservation market
with Lifor® ACF Perfusion Media by filing a Drug Master File (DMF) with
the United States Food and Drug Administration (FDA). Lifeblood has
received confirmation and a DMF control number from the FDA

"This is an important strategic move for Lifeblood in obtaining our 510k
clearance for use of Lifor® for Tissue Preservation within the allograft
market," said Joseph Fischer, President and Chief Executive Officer. "The
fact that Lifor® is Animal Component Free (ACF), can extend preservation
time at elevated temperatures and provide oxygen to cells, tissues and
organs will make it the choice for allograft processing companies. We also
believe that the Lifor® swine limb preservation study (abstract entitled
Lifor® as a Limb Preservation for Battlefield Situations) conducted this
year by one of our collaborators will enable the field of Composite Tissue
Allotransplantation to become readily available and enhance the gift of
tissue donation."

The application to the FDA provides key information about the quality of
components, materials and manufacturing processes involved in producing
Lifor®.

"The DMF is also an important step in our commercialization strategy of
Lifor®'s potential to be used in a drug or regulated manufacturing
environment by our customers. We are currently in discussions to license
and sell Lifor® internationally for applications other than Tissue
Preservation. A DMF will help expedite these collaborations, as well as
increase awareness and interest," said Joseph Fischer.

About Lifor®

Lifor® solution technology is a proprietary, patented Animal Component
Free room temperature preservation medium. Lifor® has the capability to
carry oxygen and nutrients to cells, tissues and organs. These unique
characteristics not only allows Lifor® to sustain metabolic processes and
keep cells alive, which is a critical factor in organ preservation, but
creates an in vivo-like physiologic state for organs separated from a
normal blood supply.

Lifeblood Medical, Inc. owns a patented technology that has solved the
basic properties of preserving and nourishing cells without animal based
components or toxic side effects. This discovery allows the Company to
penetrate multiple biotech and biopharmaceutical markets. The Additional
information is available at www.lifebloodmedical.com.